04:58 PM EDT, 06/26/2024 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) said Wednesday it plans to sell $200 million class A shares in an underwritten public offering, with Goldman Sachs and JPMorgan as lead book-running managers.

The company said it will grant underwriters an option to buy up to an additional 15% of shares in the offering.

Shares of the company fell about 8% in extended trading.

Price: 8.06, Change: -0.70, Percent Change: -7.99